Slightly Raising Lilly's FVE on Compelling Mid-Stage Diabetes Data; Maintaining Our Novo FVE
Lilly presented compelling phase 2b data for its dual GIP/GLP-1 receptor agonist, LY3298176, at the annual meeting of the European Association for the Study of Diabetes, and we're raising our Lilly fair value estimate to $104 from $100, which incorporates this positive data as well as the recent approval of migraine drug Emgality. While we continue to think Novo's oral semaglutide looks well positioned for a strong launch in 2020, we now believe that Lilly's GIP/GLP-1 will also see strong tracti...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.